Julkaisut
Viimeaikaiset julkaisut:
Bucci M, Rebelos E, Oikonen V, Rinne J, Nummenmaa L, Iozzo P, Nuutila P. Kinetic Modeling of Brain [18-F]FDG Positron Emission Tomography Time Activity Curves with Input Function Recovery (IR) Method. Metabolites. 2024; 14(2):114. doi: 10.3390/metabo14020114
Tato-Fernández C, Ekblad LL, Pietilä E, Saunavaara V, Helin S, Parkkola R, Zetterberg H, Blennow K, Rinne JO, & Snellman A. Cognitively healthy APOE4/4 carriers show white matter impairment associated with serum NfL and amyloid-PET. Neurobiol Dis. 2024 Mar; 192:106439. doi: 10.1016/j.nbd.2024.106439
Midlife insulin resistance, APOE genotype, and change in late-life brain beta-amyloid accumulation – A 5-year follow-up [11C]PIB-PET study. Neurobiol Dis. 2024 Jan;190:106385. doi: 10.1016/j.nbd.2023.106385.
Koivumäki M, Ekblad LL, Lantero-Rodriguez J, Ashton NJ, Karikari TK, Helin S, Parkkola R, Lötjönen J, Zetterberg H, Blennow K, Rinne JO, Snellman A. Blood biomarkers of neurodegeneration associate differently with amyloid deposition, medial temporal atrophy, and cerebrovascular changes in APOE ε4-enriched cognitively unimpaired elderly. Preprint; Research Square. https://doi.org/10.21203/rs.3.rs-3124100/v1.
Snellman A, Ekblad LL, Ashton NJ, Karikari TK, Lantero-Rodriguez J, Pietilä E, Koivumäki M, Helin S, Karrasch M, Blennow K, Zetterberg H, Rinne J. Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer’s disease. Neurobiology of Disease 2023 Jul;183:106175. doi: 10.1016/j.nbd.2023.106175.
Lantero-Rodriguez J*, Tissot C*, Snellman A*, Servaes S, Benedet AL, Rahmouni N, Montoliu-Gaya L, Therriault J, Brum WS, Stevenson J, Lussier FZ, Bezgin G, Macedo AC, Chamoun M, Mathotaarachi SS, Pascoal TA, Ashton NJ, Zetterberg H, Rosa Neto P, Blennow K. Plasma and CSF concentrations of non-phosphorylated N-terminal tau fragments associate with in vivo neurofibrillary tangle burden. Alzheimers Dement. 2023 May 15. doi: 10.1002/alz.13119.
Ekblad LL, Tuisku J, Koivumäki M, Helin S, Rinne JO, Snellman A. Insulin resistance and body mass index are associated with TSPO PET in cognitively unimpaired elderly. J Cereb Blood Flow Metab. 2023 Sep;43(9):1588-1600. doi: 10.1177/0271678X231172519.
Snellman A, Ekblad LL, Tuisku J, Koibumäki M, Ashton NJ, Lantero-Rodriguez J, Karikari TK, Helin S, Bucci M, Löyttyniemi E, Parkkola R, Karrasch M, Schöll M, Zetterberg H, Blennow K, Rinne J. APOE ε4 gene dose effect on imaging and blood biomarkers of neuroinflammation and beta-amyloid in cognitively unimpaired elderly. Alzheimers Res Ther. 2023 Apr 4;15(1):71. doi: 10.1186/s13195-023-01209-6.
Toppala S, Ekblad LL, Viitanen M, Rinne JO, Jula A. Impaired Early Insulin Response to Glucose Load Predicts Episodic Memory Decline: A 10-Year Population-Based Cohort Follow-Up of 45-74-Year-Old Men and Women. J Alzheimers Dis. 2023;92(1):349-359. doi: 10.3233/JAD-220894.
Kipinoinen T, Toppala S, Rinne JO, Viitanen MH, Jula AM, Ekblad LL. Association of Midlife Inflammatory Markers With Cognitive Performance at 10-Year Follow-up. Neurology. 2022 Nov 15;99(20):e2294-e2302. doi: 10.1212/WNL.0000000000201116.
Snellman A, Ekblad LL, Koivumäki M, Lindgren N, Tuisku J, Perälä M, Kallio L, Lehtonen R, Saunavaara V, Saunavaara J, Oikonen V, Aarnio R, Löyttyniemi E, Parkkola R, Karrasch M, Zetterberg H, Blennow K, Rinne JO. ASIC-E4: Interplay of Beta-Amyloid, Synaptic Density and Neuroinflammation in Cognitively Normal Volunteers With Three Levels of Genetic Risk for Late-Onset Alzheimer’s Disease – Study Protocol and Baseline Characteristics. Front Neurol. 2022 Feb 9;13:826423. doi: 10.3389/fneur.2022.826423. eCollection 2022.
Snellman A*, Lantero-Rodriguez J*, Emeršič A, Vrillon A, Karikari TK, Ashton NJ, Gregorič Kramberger M, Čučnik S, Paquet C, Rot U, Zetterberg H, Blennow K. N-terminal and mid-region tau fragments as fluid biomarkers in neurological diseases. Brain. 2022 Aug 27;145(8):2834-2848. doi: 10.1093/brain/awab481.
Toppala S, Ekblad LL, Viitanen M, Rinne JO, Jula A. Oral Glucose Tolerance Test Predicts Episodic Memory Decline: A 10-Year Population-Based Follow-up Study. Diabetes Care. 2021 Oct;44(10):2435-2437. doi: 10.2337/dc21-0042.
Ojala R, Hentilä J, Lietzén MS, Arponen M, Heiskanen MA, Honkala SM, Virtanen H, Koskensalo K, Lautamäki R, Löyttyniemi E, Parkkola R, Heinonen OJ, Malm T, Lahti L, Rinne J, Eskola O, Rajander J, Pietiläinen KH, Kaprio J, Ivaska KK, Hannukainen JC. Diabetes Obes Metab. 2024 Jan;26(1):251-261. doi: 10.1111/dom.15311.
Riviere ME, Langbaum JB, Turner RS, Rinne JO, Sui Y, Cazorla P, Ricart J, Meneses K, Caputo A, Tariot PN, Reiman EM, Graf A.
Effects of the active amyloid beta immunotherapy CAD106 on PET measurements of amyloid plaque deposition in cognitively unimpaired APOE ε4 homozygotes. Alzheimers Dement. 2023 Dec 25. doi: 10.1002/alz.13532.
Mummery CJ, Börjesson-Hanson A, Blackburn DJ, Vijverberg EGB, De Deyn PP, Ducharme S, Jonsson M, Schneider A, Rinne JO, Ludolph AC, Bodenschatz R, Kordasiewicz H, Swayze EE, Fitzsimmons B, Mignon L, Moore KM, Yun C, Baumann T, Li D, Norris DA, Crean R, Graham DL, Huang E, Ratti E, Bennett CF, Junge C, Lane RM. Tau-targeting antisense oligonucleotide MAPTRx in mild Alzheimer’s disease: a phase 1b, randomized, placebo-controlled trial. Nat Med. 2023 Jun;29(6):1437-1447. doi: 10.1038/s41591-023-02326-3.
Knuuti J, Tuisku J, Kärpijoki H, Iida H, Maaniitty T, Latva-Rasku A, Oikonen V, Nesterov SV, Teuho J, Jaakkola MK, Klén R, Louhi H, Saunavaara V, Nuutila P, Saraste A, Rinne J, Nummenmaa L. Quantitative Perfusion Imaging with Total-Body PET. J Nucl Med. 2023 Nov;64(Suppl 2):11S-19S.doi: 10.2967/jnumed.122.264870.
Huttunen HJ, Booms S, Sjögren M, Kerstens V, Johansson J, Holmnäs R, Koskinen J, Kulesskaya N, Fazio P, Woolley M, Brady A, Williams J, Johnson D, Dailami N, Gray W, Levo R, Saarma M, Halldin C, Marjamaa J, Resendiz-Nieves J, Grubor I, Lind G, Eerola-Rautio J, Mertsalmi T, Andréasson M, Paul G, Rinne J, Kivisaari R, Bjartmarz H, Almqvist P, Varrone A, Scheperjans F, Widner H, Svenningsson P. Intraputamenal Cerebral Dopamine Neurotrophic Factor in Parkinson’s Disease: A Randomized, Double-Blind, Multicenter Phase 1 Trial. Mov Disord. 2023 Jul;38(7):1209-1222. doi: 10.1002/mds.29426.
Rydström A, Stephen R, Kåreholt I, Darin Mattsson A, Ngandu T, Lehtisalo J, Bäckman L, Kemppainen N, Rinne J, Sindi S, Soininen H, Vanninen R, Solomon A, Mangialasche F. The role of brain integrity in the association between occupational complexity and cognitive performance in subjects with increased risk of dementia. Gerontology. 2023 Apr 18. doi: 10.1159/000530688.
Waggan I, Rissanen E, Tuisku J, Matilainen M, Parkkola R, Rinne JO, Airas L. Adenosine A2A receptor availability in cerebral gray and white matter of patients with Parkinson’s disease. Parkinsonism Relat Disord. 2023 Aug;113:105766. doi: 10.1016/j.parkreldis.2023.105766.
Laaksonen M, Rinne J, Rahi M, Posti JP, Laitio R, Kivelev J, Saarenpää I, Laukka D, Frösen J, Ronkainen A, Bendel S, Långsjö J, Ala-Peijari M, Saunavaara J, Parkkola R, Nyman M, Martikainen IK, Dickens AM, Rinne J, Valtonen M, Saari TI, Koivisto T, Bendel P, Roine T, Saraste A, Vahlberg T, Tanttari J, Laitio T. Effect of xenon on brain injury, neurological outcome, and survival in patients after aneurysmal subarachnoid hemorrhage-study protocol for a randomized clinical trial. Trials. 2023 Jun 19;24(1):417. doi: 10.1186/s13063-023-07432-8.